

PRODUCT INFORMATION

Common Name	LAG-3,CD223
Conjugate	Unconjugated
Synonyms	BMS-986016;ONO-4482
Applications	ELISA; Flow Cyt
Endotoxin	Less than 1.0 EU/ μ g by the LAL method. For <1 EU/mg requirements, please contact us for customization.
Recommended Dilutions	ELISA 1:5000-10000; Flow Cyt 1:100
Formulation & Reconstitution	Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
Host Species	Homo sapiens
IgG type	Human IgG4 - Kappa
Reactivity	Human
Target	LAG3
Uniprot ID	P18627
Description	Anti-LAG3 (relatlimab biosimilar)mAb
Delivery	In Stock
Storage&Shipping	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
Background	Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.
Usage	Research use only



Anti-LAG3 (relatlimab biosimilar) mAb ELISA

0.1 μ g of Human LAG3, His Tagged protein per well




Figure 1. ELISA plate pre-coated by 1 μ g/ml (100 μ l/well) Human LAG3, His tagged protein ([getskuurl sku="PME100512"]) can bind Anti-LAG3 Neutralizing antibody (BME100062) in a linear range of 0.6-100ng/ml.




Figure 2. Flow cytometry analysis with Anti-LAG3 mAb 1 μ g/ml (relatlimab) on HEK293 cells transfected with human LAG3 (Blue histogram) or HEK293 transfected with irrelevant protein (Red histogram).

